John C.M. Farquhar Sells 22,562 Shares of Heartflow (NASDAQ:HTFL) Stock

Heartflow, Inc. (NASDAQ:HTFL) CEO John C.M. Farquhar sold 22,562 shares of Heartflow stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $29.12, for a total value of $657,005.44. Following the completion of the transaction, the chief executive officer owned 519,397 shares of the company’s stock, valued at $15,124,840.64. This trade represents a 4.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John C.M. Farquhar also recently made the following trade(s):

• On Friday, April 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The shares were sold at an average price of $26.72, for a total value of $602,856.64.
• On Wednesday, March 18th, John C.M. Farquhar sold 9,725 shares of Heartflow stock. The stock was sold at an average price of $25.00, for a total value of $243,125.00.
• On Tuesday, March 10th, John C.M. Farquhar sold 12,837 shares of Heartflow stock. The shares were sold at an average price of $22.66, for a total value of $290,886.42.

Heartflow Price Performance

Shares of HTFL opened at $32.24 on Friday. The stock has a market capitalization of $2.78 billion and a PE ratio of -16.20. The business’s fifty day moving average price is $27.19 and its 200 day moving average price is $28.87. Heartflow, Inc. has a 12-month low of $20.13 and a 12-month high of $41.22.

Heartflow (NASDAQ:HTFL) last issued its earnings results on Thursday, May 14th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.08. The business had revenue of $52.59 million for the quarter. The business’s revenue was up 41.3% compared to the same quarter last year. As a group, research analysts anticipate that Heartflow, Inc. will post -0.78 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. JPMorgan Chase & Co. decreased their target price on Heartflow from $40.00 to $35.00 and set an “overweight” rating for the company in a research note on Thursday, March 19th. Wells Fargo & Company cut their price target on Heartflow from $38.00 to $35.00 and set an “overweight” rating on the stock in a report on Thursday, March 19th. William Blair assumed coverage on Heartflow in a research report on Monday, May 4th. They set an “outperform” rating for the company. Finally, Canaccord Genuity Group increased their target price on Heartflow from $40.00 to $43.00 and gave the stock a “buy” rating in a research report on Thursday, March 19th. Six analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Heartflow currently has an average rating of “Moderate Buy” and a consensus price target of $37.67.

Institutional Investors Weigh In On Heartflow

Large investors have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd acquired a new position in shares of Heartflow during the fourth quarter worth approximately $27,000. Russell Investments Group Ltd. bought a new stake in Heartflow during the 4th quarter valued at $45,000. Legal & General Group Plc acquired a new position in Heartflow during the 3rd quarter worth $59,000. Strs Ohio acquired a new position in Heartflow during the 4th quarter worth $99,000. Finally, Bessemer Group Inc. bought a new position in shares of Heartflow in the first quarter worth $126,000.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.